Molecular Partners Ag (MOLN) Shares Outstanding (2020 - 2026)
Molecular Partners Ag (MOLN) posted quarterly Shares Outstanding (Entity) of $50.5 million for Q4 2025, up 9.64% year-on-year from $46.1 million in Q4 2024, and up 3.58% on a QoQ basis from $48.8 million in Q2 2025.
Molecular Partners Ag (MOLN) Shares Outstanding (2020 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Shares Outstanding (Entity) for 6 consecutive years, with $50.5 million the latest figure, recorded in Q4 2025.
- Quarterly Shares Outstanding (Entity) rose 9.64% year-over-year to $50.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $50.5 million (up 9.64% YoY) and the FY2025 annual result came in at $50.5 million, up 9.64% from the prior year.
- Shares Outstanding (Entity) grew to $50.5 million in Q4 2025 per MOLN's latest filing, from $48.8 million in the prior quarter.
- Over the last five years, Shares Outstanding (Entity) for MOLN reached as high as $50.5 million in Q4 2025 and fell as low as $32.6 million in Q2 2021.
- A 5-year average of $40.6 million and a median of $40.5 million in 2023 frame the typical range for Shares Outstanding (Entity).
- Annual changes were most pronounced in 2024 — Shares Outstanding (Entity) grew 0.39% — and 2025, when it climbed 20.23%.
- Year by year, Shares Outstanding (Entity) stood at $35.0 million in 2021, then rose by 6.84% to $37.4 million in 2022, then rose by 9.54% to $41.0 million in 2023, then gained by 12.42% to $46.1 million in 2024, then grew by 9.64% to $50.5 million in 2025.
- According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $50.5 million, $48.8 million, and $46.1 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 6,012.74 Bn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 47.82 Bn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.44 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 11.23 Bn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 254.10 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 104.00 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 400.00 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 62.19 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 198.10 Mn |
| 10 | Molecular Partners Ag | 147.97 Mn | 147.97 Mn | - | 37.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 37.27 Mn |
| Dec 31, 2025 | 37.27 Mn |
| Sep 30, 2025 | 37.39 Mn |
| Jun 30, 2025 | 37.39 Mn |
| Mar 31, 2025 | 34.03 Mn |
| Dec 31, 2024 | 34.03 Mn |
| Sep 30, 2024 | 33.18 Mn |
| Jun 30, 2024 | 33.18 Mn |
| Mar 31, 2024 | 32.77 Mn |
| Dec 31, 2023 | 32.77 Mn |
| Sep 30, 2023 | 32.83 Mn |
| Jun 30, 2023 | 32.83 Mn |
| Mar 31, 2023 | 32.47 Mn |
| Dec 31, 2022 | 32.47 Mn |
| Sep 30, 2022 | 32.50 Mn |
| Jun 30, 2022 | 32.50 Mn |
| Mar 31, 2022 | 31.01 Mn |
| Dec 31, 2021 | 31.01 Mn |
| Sep 30, 2021 | 29.71 Mn |
| Jun 30, 2021 | 29.71 Mn |